Posts by: Marisa Wexler MS

Marisa Wexler MS

Marisa holds an MS in Cellular and Molecular Pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. She specializes in cancer biology, immunology, and genetics. Marisa began working with BioNews in 2018, and has written about science and health for SelfHacked and the Genetics Society of America. She also writes/composes musicals and coaches the University of Pittsburgh fencing club.

February 11, 2021February 11, 2021

Trial Testing AL101 in TNBC Doses First Patient

News

The first participant has been dosed in the Phase 2 clinical trial TENACITY, which is evaluating Ayala Pharmaceuticals‘ investigational therapy AL101 as a treatment for Notch-activated recurrent or metastatic triple ... Read more

January 28, 2021January 28, 2021

Nonprofit Highlights Importance of Global Teamwork for World Cancer Day

News

In honor of World Cancer Day on Feb. 4, the Breast International Group (BIG) emphasized the importance of wide-scale cooperation in efforts to advance cancer research. “None of BIG’s achievements ... Read more

January 18, 2021January 18, 2021

Mindfulness Can Alter Brain’s Perception of Pain in Cancer Survivors

News

Mindfulness can significantly improve brain health and pain perception in breast cancer survivors, according to a small Canadian study. The findings suggest that an eight-week mindfulness intervention can reduce activity ... Read more

December 21, 2020December 21, 2020

Margenza Approved in US for Pretreated HER2-positive Breast Cancer

News

Margenza (margetuximab-cmkb), in combination with chemotherapy, has been approved in the U.S. to treat adults with metastatic HER2-positive breast cancer who have previously received two or more anti-HER2 regimens, at ... Read more

October 12, 2020October 12, 2020

MammaCare Foundation Offers Simulator Training for Manual Breast Exams

News

The MammaCare Foundation is offering a simulator to help train healthcare professionals and students in performing manual breast exams, with the aim of improving an early diagnosis of breast cancer. Diagnosing breast ... Read more

September 24, 2020September 24, 2020

Clinical Trial Testing Estrogen Receptor Degrader GDC-9545 Enrolls First Participant

News

The first participant has been enrolled in a Phase 2 clinical trial evaluating the safety and efficacy of GDC-9545 in combination with palbociclib as an investigational treatment for postmenopausal women with estrogen receptor ... Read more

September 21, 2020September 21, 2020

Phase 1 Trial Begins Dosing Patients With Investigational Brain-penetrant HER2 Inhibitor

News

Patient dosing has begun in Zion Pharma‘s Phase 1 clinical trial in the United States to evaluate the safety of its investigational HER2 inhibitor, ZN-A-1041, in people with HER2-positive breast ... Read more

September 14, 2020September 14, 2020

First Patient Dosed in IRENE Trial Testing Immunotherapy-Oncolytic Virus Combo

News

The first participant has been dosed in the Phase 2 clinical trial IRENE, which is evaluating Incyte‘s immunotherapy retifanlimab in combination with the oncolytic virus pelareorep, by Oncolytics Biotech, as ... Read more

September 3, 2020September 3, 2020

FDA Reviewing Oral Paclitaxel Combo as Metastatic Breast Cancer Treatment

News

The U.S. Food and Drug Administration (FDA) is reviewing a new drug application from Athenex seeking approval of oral paclitaxel and encequidar (Oral Paclitaxel) for the treatment of metastatic breast ... Read more

August 24, 2020August 24, 2020

EU Approves Piqray-Faslodex Combo for Certain Advanced Breast Cancer With PIK3CA Mutation

News

The European Commission has approved Novartis‘s Piqray (alpelisib) in combination with Faslodex (fulvestrant) for the treatment of advanced or metastatic breast cancer that is hormone receptor-positive and human epidermal growth factor receptor-2-negative ... Read more